2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-182305
    VKT-17-P4-23 2411865-57-9
    VKT-17-P4-23 is a blood-brain barrier-permeable DksA inhibitor. DksA is a highly conserved transcriptional regulator in Gram-negative bacteria, with a Kd of 124 μM. Through the DksA-regulated, SPI-2-dependent survival pathway, VKT-17-P4-23 exhibits antibacterial activity against both planktonic and intracellular pathogens such as Salmonella, and also effectively combats persistent bacteria that are difficult to eliminate. VKT-17-P4-23 can be used in studies of Salmonella infection.
    VKT-17-P4-23
  • HY-182309
    SC83288 1237645-43-0 98%
    SC83288 is a Plasmodium falciparum PfDNMT2 inhibitor with an IC50 of 7 μM. SC83288 disrupts the epigenetic regulation of malaria parasites, blocks DNA replication and nuclear division, arrests the development of the asexual blood stage, induces the formation of pyknotic morphology in malaria parasites, and does not affect cytokinesis after nuclear division or parasite egress. SC83288 is applicable to malaria-related research.
    SC83288
  • HY-182316
    P-1946 449806-40-0
    P-1946 is a HIV protease inhibitor with a human HIV-1 protease Ki of 2.600 nM. P-1946 has potent and selective in vitro antiviral activity and retains full antiviral activity against HIV isolates resistant to commercially available protease inhibitors. P-1946 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection.
    P-1946
  • HY-182317
    (+)-Mosnodenvir 2043343-94-6 98%
    (+)-Mosnodenvir is an isomer of Mosnodenvir (HY-153810). Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates.
    (+)-Mosnodenvir
  • HY-182319
    Dehatrine 19634-27-6
    Dehatrine is a dibenzylisoquinoline alkaloid with antiplasmodial activity. Dehatrine can be found in the Indonesian medicinal plant Beilschmiedia madang. Dehatrine is applicable to malaria-related research.
    Dehatrine
  • HY-18233S
    Manogepix-d4 98%
    Manogepix-d4 (E1210-d4) is the deuterium labeled Manogepix (HY-18233). Manogepix (E1210) is a first-in-class, broad-spectrum and orally active antifungal. Manogepix has a mechanism of action-inhibition of fungal glycosylphosphatidylinositol (GPI) biosynthesis.
    Manogepix-d4
  • HY-182348
    LSPN959
    LSPN959 is a slow-acting indole peptidomimetic antiplasmodial agent with submicromolar activity against the Plasmodium falciparum 3D7 strain. LSPN959 does not inhibit plastid-dependent isoprenoid biosynthesis. The combination of LSPN959 with Artesunate (HY-N0193) exhibits an additive effect against Plasmodium falciparum. LSPN959 can be used in malaria research.
    LSPN959
  • HY-182409
    TSI-13-48 2254006-84-1
    TSI-13-48 (HY-182409) is a TLR inhibitor with IC50 values of 3.02, 22.3, 26.5, and 26.6 μM against TLR9, TLR7, TLR2, and TLR4, respectively. TSI-13-48 can be used in research related to systemic lupus erythematosus, polymicrobial sepsis, and cerebral malaria.
    TSI-13-48
  • HY-182461
    Deoxymorellin 1064-34-2 98%
    Deoxymorellin is a caged xanthone found in resins and fruits of Garcinia hanburyi hook. f.. Deoxymorellin exhibits cytotoxicity. Deoxymorellin can be used for research of Methicillin (HY-121544)-resistant or Methicillin-susceptible Staphylococcus aureus.
    Deoxymorellin
  • HY-182490
    Chrodrimanin H 1446801-59-7 98%
    Chrodrimanin H (Compound 13) is a sesquiterpenoid compound. Chrodrimanin H is isolated from the fungus Talaromyces primulinus H21. Chrodrimanin H blocks lipopolysaccharide-induced NO production in immune cells with an IC50 of 24.71 μM.
    Chrodrimanin H
  • HY-182495
    Penisimplicissin 873207-55-7 98%
    Penisimplicissin is a funicone-like compound and antiviral agent. Penisimplicissin reduces the expression of AhR and viral nucleocapsid protein. Penisimplicissin improves the cell viability and morphological characteristics of CCoV-infected cells. Penisimplicissin inhibits CCoV infection. Penisimplicissin can be used in studies related to canine coronavirus infection.
    Penisimplicissin
  • HY-182496
    Kanchanamycin A 181637-98-9 98%
    Kanchanamycin A is a 36-membered polyol macrolide antibiotic found in Streptomyces olivaceus Tü 4018, with high activity against Pseudomonas fluorescens, weak activity against Gram-positive bacteria and filamentous fungi, and no activity against yeasts. Kanchanamycin A inhibits growth of Pseudomonas fluorescens, Botrytis cinerea, Mucor miehei, Penicillium notatum, and Staphylococcus aureus. Kanchanamycin A is commonly used in the study of bacterial infections.
    Kanchanamycin A
  • HY-182514
    BMMP 748785-70-8
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer.
    BMMP
  • HY-182552
    Soulattrolide 65025-62-9 98%
    Soulattrolide is a non-nucleoside HIV-1 reverse transcriptase (RT) inhibitor with IC50 values of 0.34 µM for HIV-1 RT, 69.5 µM for E. coli RNase H, and >495 µM for human DNA polymerase β, and can be found in Calophyllum teysmannii latex. Soulattrolide can be used for the research of HIV-1 infection, pain, inflammation, and Mycobacterium tuberculosis infection.
    Soulattrolide
  • HY-18257R
    Rolitetracycline (Standard) 751-97-3
    Saflufenacil (Standard) is the analytical standard of Saflufenacil. This product is intended for research and analytical applications. Saflufenacil is a herbicide of the pyrimidinedione chemical class preplant burndown and selective preemergence dicot weed control in multiple crops, including corn. Saflufenacil is a potent inhibitor of protoporphyrinogen IX oxidase (PPO).
    Rolitetracycline (Standard)
  • HY-182603
    BO-653 157360-23-1 98%
    BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC50 of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection.
    BO-653
  • HY-182674
    VGD020 1322645-32-8
    VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer.
    VGD020
  • HY-182761
    Antiviral agent 81 98%
    Antiviral agent 81 is an orally bioavailable N-acylated remdesivir derivative and RdRp inhibitor with 45.3% oral bioavailability (based on active metabolite GS-441524 exposure), plasma half-life >8 h, and reduced CYP3A4 inhibition. Antiviral agent 81 exhibits activity against Coronaviridae, Flaviviridae, and Pneumoviridae, and shows no activity against Orthomyxoviridae, Herpesviridae, and Alphaviridae. Antiviral agent 81 can be used for the research of viral infections.
    Antiviral agent 81
  • HY-182894
    MR1-114
    MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection).
    MR1-114
  • HY-182895
    Influenza A virus-IN-19 3027187-19-2
    Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC50 of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a Kd of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection.
    Influenza A virus-IN-19
Cat. No. Product Name / Synonyms Application Reactivity